FDA Should Look Through IIRIS To Improve Science, Panel Says; Funding Is Worry
Executive Summary
Increasing developments in emerging sciences, such as personalized medicine, could reach roadblocks at FDA where limited resources for specialized personnel and advanced equipment may inhibit research, a report from FDA's Science Board's Subcommittee on Science and Technology shows